Cellectis S.A. (CLLS) has released an update.
Cellectis S.A., a biotech firm, has announced breakthroughs in gene-editing technology that could significantly advance the treatment of metabolic and neurological diseases. Their TALEN® editing processes have shown high efficiency in gene insertion and correction in hematopoietic stem and progenitor cells (HSPCs), with the potential to bypass the blood-brain barrier and deliver therapeutic proteins directly to the brain. These innovations promise to enhance the development of life-saving cell and gene therapies, showcasing the versatility of Cellectis’s gene-editing platform.
For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.